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Abstract
Background: Rapid, robust and reversible induction of transgene expression would significantly
facilitate cancer gene therapy as well as allow the in vivo functional study of newly discovered genes
in tumor formation and progression. The popularity of the ecdysone inducible gene switch system
has led us to investigate whether such a system can successfully regulate gene expression in a
syngeneic tumor system in vivo.
Results: MBT-2 and Panc02 carcinoma cells were transfected with components of a modification
of the ecdysone switch system driving firefly luciferase (F-Luc). In vitro luciferase expression ±
ecdysone analog GS-E indicated a robust induction with minimal baseline activity and complete
decay after 24 hours without drug. In vitro selection of MBT-2 transfected cell clones which had
complete absence of F-Luc expression in the absence of stimulation but which expressed this gene
at high levels in response to GS-E were chosen for in vivo evaluation. Tumors from engineered
MBT-2 cells were grown to 5 mm in diameter prior to GS-E administration, animals euthanized and
tumors removed at 6, 12 and 24 hours after GS-E administration and assayed for F-Luc activity. GS-
E resulted in a maximal induction of F-Luc activity at 6 hours in tumor tissue with almost complete
reversion to control levels by 12 hours.
Conclusions: This study is the first demonstration that robust and reversible transgene
expression in tumors is feasible using the ecdysone system, allowing future rapid in vivo functional
characterization of gene function or gene therapy applications.
Background
Rapid, robust and reversible induction of transgene ex-
pression would significantly facilitate certain applica-
tions of gene therapy and the study of cancer biology.
Several inducible systems have been developed to regu-
late gene expression at the transcriptional level in a tem-
poral and quantitative manner. [1–4] These include
systems based on heat shock, heavy metal ion, tetracy-
cline, steroid, or ecdysone hormone induction. For in
vivo applications, tetracycline, steroid, rapamycin and,
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and in recent years. Currently the most popular induci-
ble system is based on components of the tetracycline re-
sistance operon, which has seen use in both tumors [2,5]
as well as transgenic animals. [6] However, these sys-
tems have limitations the most important being the sig-
nificant background expression. Recently, the
development of an inducible system based on the insect
steroid ecdysone and the nuclear receptor that mediates
its effect [7]has provided an alternative that may circum-
vent these limitations. The use of ecdysone inducible
transgene expression in vitro [8,9] and in transgenic
mice [10] has recently been demonstrated. The use of
this system in vivo has several potential advantages over
other regulatory systems. The ecdysone hormones do not
affect mammalian physiology like glucocorticoids or pro-
gestins and are not known to be toxic or teratogenic like
tetracycline [11] allowing their use in both developmen-
tal studies with transgenic animals as well as in the con-
text of gene therapy and tumor biology studies in mature
animals.
The popularity of the ecdysone inducible gene switch
system has led us to investigate its characteristics as a
regulator of transgene expression in tumor xenografts
since to our knowledge, this has not yet been reported.
Prior to evaluating this in vivo, we have thoroughly ex-
amined the kinetics of this switch in vitro in 2 different
tumor cell lines using 2 different reporters in order to
evaluate the generality of these observations. The in vivo
evaluation was carried out in a model of highly aggres-
sive murine bladder cancer, which has previously been
used for testing various therapeutic interventions.
[12,13] These bladder cell lines were transfected with a
novel ecdysone system regulating the expression of fire-
fly luciferase and then injected subcutaneously into syn-
geneic hosts. Treatment of the animals with ecdysone
analog A/-(3-methoxy-2-ethylbenzoyl)-A/'-(3,5-
dimethylbenzoyl)-A/'-tert-butyl hydrazine (GS-E) was
then carried out with subsequent evaluation of in vivo
gene expression. Our data suggests that in vivo induction
of tumor transgene expression is feasible and reversible
using an ecdysone switch and opens the avenue for the
efficient functional characterization of many newly dis-
covered genes as well as novel gene therapy approaches.
Results
Derivation of mouse tumor cell lines containing a novel 
gene regulatory mechanism
A description of the plasmids encoding the two compo-
nents of an ecdysone inducible transcription activation
system was reported previously [14]. The plasmids
pGAL4-EcR and pVP16-mRXR encode proteins which
heterodimerize and regulate transcription upon the ad-
dition of ecdysone type ligands (Figure 1A). Using these
plasmids as a starting point, a novel indicator of the in-
ducible gene expression system was constructed as fol-
lows. The CMV promoter and enhancer were removed
from the mammalian expression vector pCI-neo (Prome-
ga). Inserted in its place were five copies of the GAL4
binding site followed by the minimal promoter region of
the major late promoter from adenovirus (from pG5-luc
(Promega)) and the coding region for the enhanced
green fluorescent protein (EGFP) gene (from pEGFP-
N1) (Clontech). The control plasmid, pRL-TK (Prome-
ga), expresses the Renilla luciferase gene under the con-
trol of the HSV thymidine kinase (TK) promoter. This
plasmid provides constitutively high gene expression
and we use it as an indicator of the number of tumor cells
present in the tissue samples harvested from mice in the
in vivo experiments.
MBT-2 cells, a mouse urothelial cancer cell line, or
Panc02, a mouse ductal adenocarcinoma, were trans-
fected by electroporation with a mixture of the four plas-
mids; the two components of the gene expression
system, pVP16-mRXR and pGAL4-EcR; the indicator
and selection plasmid, pGAL4-EGFP-SV40-neo; and the
internal control plasmid, pRL-TK. Stably transfected
MBT-2 cells were selected in media containing 500 µg/
ml G418 and Panc02 cells in 700 µg/ml G418 for three
weeks after which there were many large cell colonies on
each transfection plate. The drug resistant cells were
harvested by trypsinization, pooled, and cloned to single
cells by limiting dilution in 96 well plates. When colonies
had grown in a subset of the wells in the 96 well plate,
fresh media containing GS-E was added to all wells to a
final GS-E concentration of 5 µM. Cells were treated for
24 hours and all wells were visualized with the fluores-
cent microscope to detect EGFP expression.
At least 96 clones of MBT-2 or Panc02 clones demon-
strating fluorescence were trypsinized and expanded
into 24 well plates. When the clones had reached at least
50% confluence in the 24 well plate, GS-E was again add-
ed to 5 µM to verify the earlier observation of induced
EGFP expression. Four clones of each cell line exhibiting
high levels of EGFP expression were expanded for fur-
ther analysis. Each cell line was transiently transfected
with 1 µg pFR-luc and carrier DNA. Luciferase activity in
the DMSO treated wells was similarly low in all wells of
the triplicates of the eight transfections. After treatment
with 15 µM GS-E, three of the four MBT-2 clonal cell
lines had a two-fold or lower increase in luciferase activ-
ity. Clone #2 had 8.4-fold higher luciferase activity with
GS-E treatment. This clone, designated MBT2+RheoS-
witch-2, was used for further development. In a similar
analysis, Panc02+RheoSwitch-3 and -4 demonstrated
induction levels of 366- and 428-fold respectively. NoPage 2 of 12
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Plasmid constructs used in cell line generation.(A) Plasmids used in generating RHeoSwitch Cell Lines.(B) Reporter
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observed with GS-E treatment in all cell lines.
Stable introduction of inducible reporter genes into the 
RHeoSwitch tumor cell lines
The MBT-2+RHeoSwitch-2 cell line containing the RHe-
oSwitch expression system was used for the introduction
of two different reporter gene systems. The plasmid,
pG5-luc, contains the GAL4 response element express-
ing the luc+ gene (Figure 1B). The vector pGAL4-SEAP
containing the GAL4 response element and the coding
region for the SEAP protein, a unique, second reporter
gene, was also used. Each of these vectors was linearized
and co-transfected with linearized pSV40-Zeo by elec-
troporation into the MBT-2+RHeoSwitch-2 cells. Cells
were selected in media containing 400 µg/ml Zeocin un-
til colonies appeared in each of the plates. Zeocin resist-
ant cells were trypsinized, pooled, and single cell cloned
by limited dilution in 96 well plates. Aliquots of the
pooled cells used for cloning were also plated in tripli-
cate, treated with GS-E or DMSO for 24 hrs. Assays for
the appropriate reporter in each cell pool showed induc-
tion ratios of 17-fold for the luciferase transfected cells
and 22-fold for the SEAP transfected cells. This verified
the presence of the GS-E inducible reporter genes (luci-
ferase or SEAP) in the cloned pool of cells.
Clones were grown in Zeocin containing media until col-
onies appeared. Eighty-four luciferase transfected clones
and 113 SEAP transfected clones were transferred from
the 96 well plates and duplicate wells of each were treat-
ed with either DMSO or 15 µM GS-E in DMSO for 24
hours. Each pair of wells was assayed for reporter protein
activity and clones demonstrating basal levels of activity
in the DMSO treated sample and high levels in the GS-E
sample were further expanded for additional testing.
These cell clones were plated in a six well plate and trip-
licate wells were treated with DMSO or 15 µM GS-E for
48 hours. Luciferase clone MBT-2+RHeoSwitch-2+luc-
5B3 was chosen to be used for a more detailed analysis of
the properties of the gene induction system.
The inducible reporter gene plasmids, pG5-luc and
pGAL4-SEAP, were transfected into the Panc02+RHe-
oSwitch-3 and -4 cells and stable transfectants were iso-
lated as they were into the MBT-2+RHeoSwitch cells.
Multiple Zeocin resistant cell clones from the four trans-
fections (36 Panc02+RHeoSwitch-3+luc, 75
Panc02+RHeoSwitch-4+luc, 8 Panc02+RHeoSwitch-
3+GAL4-SEAP, 98 Panc02+RHeoSwitch-4+SEAP) were
plated in duplicate and treated with DMSO or 15 µM GS-
E. A sample of clones with basal level of reporter in the
DMSO treated sample and the highest level of reporter in
the GS-E treated sample were selected to be expanded
and further tested.
Multiple assays in triplicate on the GAL4-SEAP trans-
fected clones gave induction levels ranging from 118- to
551-fold for the best five Panc02+RHeoSwitch-3 clones
and from 52- to 486-fold for the best twelve
Panc02+RHeoSwitch-4 clones. Clones Panc02+RHeoS-
witch-3+GAL4-SEAP-5 and -8 and Panc02+RHeoS-
witch-4+GAL4-SEAP-8 and -9 were used for further
characterization. Multiple assays in triplicate on the
pG5-luc transfected clones yielded induction levels rang-
ing from 32- to 51-fold for the four best Panc02+RHeoS-
witch-3 clones and from 7- to 94-fold for the four best
Panc02+RHeoSwitch-4 clones. Clones Panc02+RHeoS-
witch-3+luc-3Cl AND -1B1 and Panc02+RHeoSwitch-
4+luc-3A1 and -4B3 were used for further characteriza-
tion. These clones do not exhibit the high levels of in-
duced GFP expression that was seen in the initial
RHeoSwitch transfected cells. This may be explained by
the fact that they were selected on the basis of the induc-
tion level of the reporter gene expression, however, con-
trary to the initial screen, the level of induction of GFP
was not used as a selection criteria and cell clones in
which the expression of GFP has variegated were isolat-
ed. A summary flowchart of the cell line selection and
characterization is shown in figure 2.
Characterization of the novel gene regulatory mechanism 
in vitro
Treatment of luciferase clone 5B3 with 15 µM GS-E for
48 hours consistently induced luciferase levels from near
background with only DMSO added, to nearly 150-fold
(Table 1) when adjusted for non specific R-Luc induction
which was approximately 1.2 fold. In order to under-
stand the induction kinetics of the inducible system, cell
clone MBT-2+RHeoSwitch-2+luc-5B3 was treated with
GS-E and cells were harvested at different times to deter-
mine the time course of gene induction. At each time
point, the control and treated cells were collected in pas-
sive lysis buffer and dual luciferase assays performed.
Data were plotted as a GS-E (RLU1/RLU2)/Control
(RLU1/RLU2) ratio (as in Table 1) fold induction over
the 0 time point which was set empirically as 1. This data
shown in Figure 3A indicates that gene expression is in-
creased by 8 hours and reaches maximum induction by
24 hours. The internal control, Renilla luciferase, in-
crease steadily with time, reflecting the increase in cell
number, but the increase was the same with DMSO or
GS-E treatment (raw data not shown but effect account-
ed for in the calculation as defined above).
The sensitivity of the gene expression system to varying
doses of GS-E was determined by treating duplicate sam-
ples of clone MBT-2+RHeoSwitch-2+luc-5B3 with vary-
ing concentrations of GS-E for 24 or 48 hours and dual
luciferase assays were performed on the cell lysates (Fig-
ure 3B). Data were plotted as a GS-E(RLU1/RLU2)/Con-Page 4 of 12
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A summary flowchart of the cell line selection and characterizationPage 5 of 12
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Time and dose response kinetics of luciferase in response to GS-E.(A) Cell clone MBT-2+RHeoSwitch-2+luc-5B3
was treated with GS-E and cells were harvested at different times to determine the time course of gene induction. At each
time point, the control and treated cells were collected in passive lysis buffer and dual luciferase assays performed. Data were
plotted as a GS-E (RLU1/RLU2)/ Control (RLU1/RLU2) ratio (as in Table 1) fold induction over the 0 time point which was set
empirically as 1. The internal control, Renilla luciferase, increase steadily with time, reflecting the increase in cell number, but
the increase was the same with DMSO or GS-E treatment (raw data not shown but effect accounted for in the calculation as
defined above).(B) The sensitivity of the gene expression system to varying doses of GS-E was determined by treating dupli-
cate samples of clone MBT-2+RHeoSwitch-2+luc-5B3 with varying concentrations of GS-E for 24 hours and dual luciferase
assays and data analysis were performed on the cell lysates as described in (A) above.Page 6 of 12
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over the 0 drug concentration which was set empirically
as 1. These results show an increase in gene inducing ac-
tivity with increasing GS-E concentrations up to 10 µM.
A significant increase was seen with as little as 1 µM GS-
E. No change was seen in the level of the internal control
Renilla luciferase with varying concentrations of GS-E
(raw data not shown but effect accounted for in the cal-
culation as defined above).
The decay characteristics of the induction were also stud-
ied. After a 24 hour incubation, the medium containing
GS-E was removed and the cells washed three times with
complete medium without GS-E. The cells were then re
incubated for various durations. At set intervals replicate
wells were removed and dual luciferase assays were per-
formed on the cell lysates (Figure 4A). This data indi-
cates that the GS-E mediated induction is completely
reversible and that this occurs within 48 hours.
Similar dose response and time course of induction of
gene expression experiments were performed on the
Panc02 cells containing the RHeoSwitch and the induci-
ble reporter genes. The time course of gene induction
demonstrated for four independent Panc02+RHeoS-
witch+luciferase cell clones each showed an increase
within 12 hours of GS-E treatment and reached the max-
imum induction by 24 hours. Four independent
Panc02+RHeoSwitch+SEAP clones also induced expres-
sion by 12 hours but the level of SEAP activity continued
to increase for 72 hours, possibly due to the accumula-
tion of the enzyme in the cell culture media over the en-
tire treatment time. Treatment of five of these
independent Panc02+RHeoSwitch+reporter gene
clones with varying doses of GS-E consistently yielded a
significant induction in gene expression with 1 µM GS-E
(23.5-fold induction over DMSO treatment alone) and a
maximal induction with 15 µM GS-E (80.2-fold induc-
tion over DMSO). The dose response and time course of
induction in the Panc02 cells were similar to the results
seen in experiments on the MBT-2 cells. These results
show that the RHeoSwitch gene induction system gives
consistent results independent of the cell type being
used, the reporter gene used to assess the activity, as well
as the chromosomal integration site of the DNA encod-
ing the RHeoSwitch components (compare
Panc02+RHeoSwitch-3 and -4 described above) or the
integration site of the reporter gene DNA (compare mul-
tiple reporter clones from each of three RHeoSwitch
clones described above).
In vivo results
The potency and favorable kinetics of GS-E as an ecdys-
one-system inducer in vitro in both the pancreatic and
bladder cell lines led us to evaluate its performance in
vivo in a bladder xenograft model. To measure the phar-
macokinetics of GSE mediated gene induction in ani-
mals, we inoculated the MBT-2 murine bladder cancer
cell line into syngeneic mice and after the tumors
reached 0.4–0.5 mm in diameter, the mice were treated
Table 1: Summary of GS-E induction of luciferase activity in clone MBT-2 + RHeoSwitch #2 + pGS-luc - 5B3
Experiment RLU1^ RLU1 RLU2' RLU2 RLU1/RLU2 RLU1/RLU2
CON GS-E T/C CON GS-E T/C CON GS-E T/C
A 4457* 992343 222.6 543227 678517 1.2 0.01 1.46 178.3
B 4123 948272 230.0 579818 709519 1.2 0.01 1.34 188.0
C 4771 982058 205.8 658164 823060 1.3 0.01 1.19 164.6
D 3915 597044 152.5 537789 720480 1.3 0.01 0.83 113.8
E 1757 350947 199.7 75614 95031 1.3 0.02 3.69 158.9
F 1405 314349 223.7 232147 300061 1.3 0.01 1.05 173.1
G 1343 234858 174.9 174883 207357 1.2 0.01 1.13 147.5
H 3958 737902 186.4 197599 227480 1.2 0.02 3.24 161.9
1 3822 710260 185.8 209591 251976 1.2 0.02 2.82 154.6
J 3714 692231 186.4 218191 259666 1.2 0.02 2.67 156.6
Mean 196.8 Mean 1.2 Mean 159.7
SD 24.4 SD 0.1 SD 20.1
N 10 N 10 N 10
CON: control carrier applied only Only 48 hour time-points displayed in this summary ^RLU1 is expression of firefly luciferase from the inducible 
promoter 'RLU2 is expression of Renilla luciferase from the constitutive TK promoter *All data points shown are the average from duplicate or 
triplicate samplesPage 7 of 12
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(A) The decay characteristics following initial induction of luciferase by GS-E. After a 24 hour incubation using sim-
ilar conditions to those described in figure A, the medium containing GS-E was removed and the cells washed three times with
complete medium without GS-E. The cells were then re incubated for various durations as shown in the graph. At set intervals
triplicate wells were removed and dual luciferase assays were performed on the cell lysates. Error bars indicate mean +/- one
standard error for triplicate experiments. (B) In vivo induction of gene expression in tumor xenografts. Six-to-8 week-
old C3H/He origin mice were given injections in the anterior flank (2 sites per mouse) with 106 MBT-2 tumor cells suspended
in 0.1 ml of serum free medium. Mice were examined every week, and tumors were measured with calipers in the greatest 2
diameters. When tumors reached 5 mm in greatest diameter, mice were injected intraperitoneally with either 45 milligrams of
GS-E dissolved in 90 µl of DMSO and 360 µl of sesame oil (GS-E Addition) or with equivalent volumes of DMSO and 360 µl of
sesame oil alone (Control). Cohorts of mice were euthanized at various time points following drug administration or vehicle
administration and tumors processed for luciferase activity as described in the materials and methods section. Error bars indi-
cate mean +/- one standard error for 4–6 tumors.Page 8 of 12
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ulation, the tumors were excised and analyzed for luci-
ferase induction. Luciferase protein was chosen
primarily because its 3–4 hour half-life in mammalian
cell allows precise kinetic studies [15]. The renilla luci-
ferase was used as an internal control in addition to un-
treated mice. Data shown in Figure 4B indicates that
induction of luciferase activity in tumor xenografts is
prompt, peaking between 6–12 hours. In addition, decay
of the effect occurs swiftly and baseline expression levels
are reached by 12–24 hours. Although available to us, the
identification of cell specific expression within the tumor
using the induction of GFP in these tumor cells was com-
plicated by the decrease in the level of GFP expression
(data not shown), presumably due to position effect var-
iegation of the transfected DNA as well as poor quantita-
tion ability.
Discussion
Methods devised to control gene expression must allow
for rapid, robust, precise, and reversible induction of
gene activity. Because steroids are small lipophilic mole-
cules that penetrate all tissues and are quickly metabo-
lized and cleared, they appear to be ideal inducers for
developing gene regulation systems that fulfill these cri-
teria. To exploit the pharmacokinetics of steroids while
eluding the potential complications of the use of a mam-
malian hormone as the inducer, the Evans laboratory de-
veloped an inducible system based on the insect steroid
ecdysone and the nuclear receptor that mediates its ef-
fects. [7] This system is comprised of a chimeric protein
composed of the VP16 activation domain (Vg) fused to an
ecdysone receptor (EcR) with altered DNA-binding spe-
cificity heterodimerizes with the retinoid X receptor
(RXR) and binds a unique synthetic response element
not recognized by natural nuclear hormone receptors.
Upon exposure to the ecdysone analog muristerone A
(murA), the VgEcR/RXR complex efficiently induces the
expression of reporter genes in mammalian cells and
transgenic animals. In the RHeoSwitch gene expression
system, the properties of the chimeric receptors have
been optimized through the analysis of a series of trunca-
tion and site-directed mutations (Palli, et.al., manuscript
in preparation). This study demonstrates the utility of a
first generation system in vitro and in vivo and subse-
quent modified versions of the RHeoSwitch will be sen-
sitive to lower concentrations of ligand and result in
higher levels of induced gene expression (see
[www.RHeoGene.com] ).
The popularity of the ecdysone-inducible gene switch led
to the unexpected rapid depletion of murA stocks, the
primary inducer used in the system. MurA was isolated
in the early 1970s from the seeds of kaladana (Ipomoea
calonyction), a plant native to the southern slopes of the
Himalayas. [10] The difficulty in obtaining kaladana
seeds prompted efforts to seek alternative inducers de-
rived from more common plants or synthetic analogs
such as GS-E. GS-E is one of a family of diacylhydrazines
that have been found to act as non-steroidal ecdysone
mimics that can function as gene inducers [16].
The avalanche of new genes resulting from completion of
the genome project has accentuated the need to develop
methods to determine gene function. The requirement
for tight regulation, easy titration and minimal back-
ground expression is particularly important in the study
of genes such as tumor suppressors or cell cycle regula-
tory genes for which cell lines stably expressing the prod-
uct can rarely be made. In addition, deliberate
manipulation of gene activity is also an indispensable
tool for clinical applications such as gene therapy. The
strengths of the ecdysone-inducible system appear to be
its tight regulation, its dose responsiveness, and the favo-
rable uptake and clearance kinetics of the inducer, which
results in rapid gene switching. Thus it appears ideal for
both the in vitro and in vivo study of newly characterized
genes in their role in tumor formation and progression.
In vitro data indicates that our constructs when used in
combination with GS-E, offer an excellent induction pro-
file and rapid decay of gene expression when the com-
pound is removed from in vitro culture. Importantly, we
have demonstrated similar kinetics for 2 different cancer
cell lines with 2 different reporters (F-luc and SEAP)
thus validating the generality of the observed results. In
addition, these constructs are also associated with a low
baseline gene expression level allowing the study of
genes whose expression may be incompatible with the
generation of constitutively expressing clones. A recent
report showed that the expression of nonmuscle myosin
heavy chain-B induced by Muristerone A in vitro [8] sup-
pressed the subsequent tumorigenicity of the implanted
cells in vivo.
The potency and favorable kinetics of the cell lines we de-
veloped in conjunction with GS-E as an ecdysone-system
inducer in vitro in both the pancreatic and bladder cell
lines led us to evaluate the performance of this system in
vivo in a bladder cancer xenograft model. The advantag-
es of the MBT-2 murine bladder tumor model are several
fold. First, it was derived by chemical carcinogenesis, the
most common known etiologic factor in bladder cancer.
Second, when inoculated orthotopically it reproduces
the biology of human muscle invasive bladder cancer.
Thirdly, it has been widely used as a model system of var-
ious therapeutic interventions in bladder cancer. [12,13]
Interestingly, our data indicates that the kinetics of in-
duction of tumor luciferase in response to GS-E mirror
those observed with transgenic mice in response to Po-
nA. [10] This finding may indicate that despite their usePage 9 of 12
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with similar kinetics to that in normal cells thus implying
a general utility in studies of various histological tumor
types. In addition, comparison of the in vivo (Figure 4B)
and in vitro (Figure 3A) induction curves reveals roughly
similar time to peak induction despite the fact that the in
vivo experiments were carried out with a mixture of GS-
E in sesame seed oil, which purportedly slows its deliv-
ery. [9]
Although available to us, the identification of cell specific
expression within the tumor using the induction of GFP
in these tumor cells was complicated by the decrease in
the level of GFP expression, presumably due to position
effect variegation of the transfected DNA. In addition,
the utility of GFP for the localization of gene expression
in vivo, particularly in conditions of hypoxia, such as tu-
mors, has been recently been questioned [17]. Finally,
quantitative analysis of tumor GFP induction is difficult
and less reliable than other reporters such as luciferase.
Therefore we have limited our in vivo experiments deter-
mining the general level of gene induction within the tu-
mor by using a luciferase reporter which has been proven
to be reliable in vivo.
Conclusions
We have used a modified ecdysone reporter system
which has favorable baseline and induction kinetics in
response to a novel ecdysone analog GS-E in murine tu-
mors in vitro. We have demonstrated the general appli-
cability of this system by demonstrating its use in two
different mouse tumor cell lines, integration of the RHe-
oSwitch DNA components at multiple chromosomal lo-
cations, as well as with 2 different gene reporters,
luciferase, and SEAP. We have presented data that is the
first demonstration of tumor cell lines stably transfected
with an ecdysone inducible constructs tested in vivo
demonstrating that in vivo these constructs coupled with
GS-E allow rapid and robust induction of gene expres-
sion in tumor xenografts. Finally, due to the rapid decay
of gene expression following maximal activation, this
system can be easily titrated for the duration of the in-
duction necessary by using slow release formulations
such as ALZET mini pumps [18]. The postgenomic era
has accentuated the need to develop methods to deter-
mine in vivo gene function in cancer and this ecdysone
system may be a useful approach to address this.
Materials and Methods
Cell culture and plasmid DNA constructs
MBT-2 murine urothelial cancer cells and their culture
conditions for passage were previously described. [12]
The murine ductal cell pancreatic adenocarcinoma cell
line, Panc02 [19], was kindly provided by Dr. James Nel-
son, MD Anderson Cancer Center. Plasmid DNA was
prepared by the "EndoFree Plasmid Maxi kit" from Qia-
gen (Valencia, CA) using the manufacturer's procedure.
Cells were simultaneously co-transfected by electropora-
tion (Gene Pulser, Bio-Rad Inc.) with pGAL4-EcR,
pVP16-mRXR, pRL-TK (Renilla luciferase) and pGAL4-
EGFP. The plasmids pGAL4-EcR encodes a fusion pro-
tein between the yeast GAL4 DNA binding domain and
the ligand binding domain of the ecdysone receptor from
the spruce budworm, Choristoneura occidentalis. Plas-
mid pVP16-mRXR encodes a fusion protein between the
transcriptional transactivator VP16 from Herpes simplex
virus (HSV) and the mouse RXR protein. The vector
pRL-TK (Promega), expressing the Renilla luciferase en-
zyme from the HSV thymidine kinase (TK) promoter,
was included as an uninduced constitutively expressed
internal control. The vector pGAL4-EGFP was construct-
ed from pCI-neo (Promega) by replacing the CMV pro-
moter and enhancer with a fragment from pG5-luc
(Promega) containing the 5xGAL4 recognition sequenc-
es and the minimal promoter from the adenoviral late
promoter and the EGFP gene from pEGFP (Clontech). In
addition to the GAL4-EGFP expression cassette, this
plasmid contains the neomycin resistance gene under
the control of the SV40 promoter and enhancer for selec-
tion of transfected cells in G418.
Transfection and isolation of clones stably transfected 
with inducible reporter gene plasmids
Cells were transfected by electroporation with mixtures
of the four plasmids which had been linearized by re-
striction enzyme digestion. Following transfection, cells
were allowed to recover for 24 h prior and were then se-
lected in 500 µg/ml G418 for MBT-2 cells and 700 µg/ml
G418 for Panc02 cells for three weeks. Cells were then
cloned by limited dilution into 96 well plates. Expression
of green fluorescent protein (GFP) was induced by addi-
tion of GS-E (A/-(3-methoxy-2-ethylbenzoyl)-A/'-(3,5-
dimethylbenzoyl)-A/'-tert-butylhydrazine). GS-E is a
member of the bisacylhydrazine chemical family which
has been shown to have no adverse effects over a broad
dosage range in mammals. [11] The 96 well plates were
visualized under a fluorescent microscope before and af-
ter addition of the compound. Clones exhibiting low
background of green fluorescence prior to addition of the
compound and high levels following the addition were
selected for further transfections.
Cell clones were transiently transfected using Superfect
reagent with 1 µg per well of 6 well plate with either pFR-
luc (Promega) or pGAL4-SEAP (secreted alkaline phos-
phatase) (provided by Dr. R. Herzig, Rheogene Inc.) and
3 µg carrier DNA (pLITMUS, New England Biolabs). To
three wells, DMSO was added to a final concentration of
0.3% v/v. GS-E in DMSO was added to the remaining
three wells to a final GS-E concentration of 15 µM andPage 10 of 12
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hours, at which time they were collected in Passive Lysis
Buffer and the activity of firefly and Renilla luciferase in
the cell extract was determined. The clone exhibiting the
highest level of induced gene expression was then used
for further development. These cells where in turn co-
transfected with pSV40/Zeo2 (Invitrogen) and pG5-luc
(Promega), encoding firefly luciferase or pGAL4-SEAP
and MBT-2 cells were selected in 400 µg/ml Zeocin and
Panc02 cells in 500 µg/ml Zeocin. Zeocin resistant cells
were then cloned by limiting dilution into 96 well plates.
Replica plates were then created and induction of luci-
ferase activity in response to GS-E carried out as for GFP.
Clones exhibiting low background luciferase expression
prior to addition of the compound and high levels follow-
ing the addition were selected for further in vivo and in
vitro study.
Measurement of reporter protein levels in vitro and in vivo
To determine the luciferase activity, cells or tissues were
lysed in Passive Lysis Buffer (Promega) and assayed for
firefly (F-luc) and Renilla (R-Luc) luciferase according to
the Promega Luciferase assay kit instructions in a Turner
Designs (Sunnyvale, CA) TD-20/20 or a PharMingen
Monolight 3010 luminometer. The luciferase activity
was recorded as Relative Light Units (RLU).
For the determination of SEAP levels, cells were treated
with DMSO or GS-E for 48 hours. Media was removed
from all cultures and either assayed or stored at -20 de-
grees until assayed. Assays were performed using the
chemiluminescent SEAP assay procedure as described
by the manufacturer in the Great EscAPe SEAP Assay
system (Clontech). The chemiluminescent signal was
measured with a PharMingen Monolight 3010 luminom-
eter and recorded as Relative Light Units (RLU).
In vivo tumor assays
Six-to-8 week-old C3H/He origin mice were obtained
from Taconic Farms  [www.taconic.com]  and main-
tained strictly according to approved Institutional Ani-
mal Care and Use Committee protocols. Food and water
were provided ad libitum. Cohorts of mice were given in-
jections in the anterior flank (2 sites per mouse) with 106
tumor cells suspended in 0.1 ml of serum free medium.
Mice were examined every week, and tumors were meas-
ured with calipers in the greatest 2 diameters. When tu-
mors reached 5 mm in greatest diameter, mice were
injected intraperitoneally with either 45 milligrams of
GS-E dissolved in 90 µl of DMSO and 360 µl of sesame
oil or with equivalent volumes of DMSO and 360 µl of
sesame oil alone. Cohorts of 3 mice were euthanized 6, 12
and 24 hours following drug administration and cohorts
of 2 mice euthanized 6 and 24 hours following vehicle ad-
ministration and tumors processed for luciferase activity
as described above. To evaluate the reporter induction,
the ratio of RLU from firefly (F-luc) and Renilla (R-Luc)
luciferase was evaluated (RLU{F-luc}/RLU{R-luc}).
This time course was based on the pharmacokinetics of
PonA following this route of administration. [10]
Statistical analysis
All in vitro assays were performed using duplicate or
triplicate samples and error bars represent one standard
error from the mean. Figures consist of a representative
experiment carried out at least 2–3 times with similar re-
sults. Data were plotted and statistical analysis was ac-
complished using the STATISTICA for Windows
computer program (StatSoft, Inc. Tulsa, OK).
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